Wedbush restated their outperform rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report released on Tuesday. The firm currently has a $40.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $42.00.
LXRX has been the subject of a number of other research reports. BidaskClub upgraded Lexicon Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, January 30th. Zacks Investment Research lowered Lexicon Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, January 31st. ValuEngine lowered Lexicon Pharmaceuticals from a sell rating to a strong sell rating in a research note on Friday, February 2nd. JPMorgan Chase lowered Lexicon Pharmaceuticals from a neutral rating to an underweight rating and cut their price target for the stock from $15.00 to $10.00 in a research note on Wednesday, February 14th. Finally, Needham & Company LLC lowered Lexicon Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, February 23rd. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. Lexicon Pharmaceuticals presently has an average rating of Hold and a consensus price target of $24.40.
NASDAQ:LXRX opened at $10.00 on Tuesday. The company has a quick ratio of 2.70, a current ratio of 2.72 and a debt-to-equity ratio of 8.85. The firm has a market capitalization of $1.06 billion, a PE ratio of -7.87 and a beta of 0.42. Lexicon Pharmaceuticals has a one year low of $7.67 and a one year high of $18.00.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.03. The firm had revenue of $25.21 million during the quarter, compared to analyst estimates of $25.30 million. Lexicon Pharmaceuticals had a negative return on equity of 213.32% and a negative net margin of 140.09%. Lexicon Pharmaceuticals’s revenue was up 37.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.33) EPS. sell-side analysts expect that Lexicon Pharmaceuticals will post -1.33 EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the business. Malaga Cove Capital LLC increased its stake in Lexicon Pharmaceuticals by 37.5% in the 4th quarter. Malaga Cove Capital LLC now owns 59,387 shares of the biopharmaceutical company’s stock worth $587,000 after buying an additional 16,198 shares in the last quarter. Clearbridge LLC increased its stake in Lexicon Pharmaceuticals by 35.8% in the 4th quarter. Clearbridge LLC now owns 1,189,097 shares of the biopharmaceutical company’s stock worth $11,748,000 after buying an additional 313,350 shares in the last quarter. Aperio Group LLC purchased a new stake in Lexicon Pharmaceuticals in the 4th quarter worth $127,000. Tekla Capital Management LLC purchased a new stake in Lexicon Pharmaceuticals in the 4th quarter worth $2,754,000. Finally, Artal Group S.A. boosted its holdings in shares of Lexicon Pharmaceuticals by 1.3% during the 4th quarter. Artal Group S.A. now owns 58,274,650 shares of the biopharmaceutical company’s stock valued at $575,754,000 after purchasing an additional 756,673 shares during the last quarter.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.